What’s New: The treatment landscape for cerebral metastases in metastatic lung cancer patients has evolved due to advancements in targeted molecular therapies and immuno-oncology, which can now effectively cross the blood-brain barrier.

Importance: This development is significant because previously, cerebral metastases were seen as a poor prognostic factor, leading to the exclusion of these patients from therapy studies.

Contribution to Literature: The abstract highlights the importance of a multidisciplinary approach in the treatment of brain metastases, taking into account various factors such as metastasis characteristics, patient’s overall health, comorbidities, life expectancy, patient’s preferences, tumor biology, and extracranial tumor burden. It emphasizes the combination of systemic therapies with neurosurgical and radiotherapeutic interventions to improve patient prognosis.

Summary: The treatment of brain metastases in lung cancer has become more effective due to therapies that penetrate the blood-brain barrier. Treatment decisions are now more complex and personalized, considering a wide range of factors and involving a multidisciplinary team. The integration of systemic, neurosurgical, and radiotherapeutic treatments offers a more optimistic outlook for these patients.